President Trump’s Marijuana Order: What It Really Means for Patients, Taxes and CBD

On Dec. 18, 2025, President Donald Trump signed an executive order directing federal agencies to move marijuana from Schedule 1 to Schedule 3 under the Controlled Substances Act.

The White House and many trade outlets quickly framed the action as the most significant federal shift on cannabis since 1970.

The order instructs the Justice Department and Drug Enforcement Administration to “expeditiously” carry out Trump marijuana rescheduling, and it links that move to both tax relief for the legal cannabis industry and a push to explore limited Medicare coverage for CBD.

For patients in Arizona and across the country, the moment is historic and confusing at the same time.

Federal officials are finally acknowledging that marijuana has accepted medical use, yet cannabis remains illegal at the federal level for most purposes. Headlines promise 280E tax relief, safer banking and CBD “for seniors on Medicare.”

The fine print says implementation will take months or even years, many criminal penalties will remain in place, and Medicare changes are still at the proposal or pilot stage.

This is where medical educators and certifying practices such as The Marijuana Doctor become essential. Someone has to translate Trump marijuana rescheduling and the emerging Medicare CBD conversation into practical guidance for patients who simply want safe, affordable care.

How we got to Trump marijuana rescheduling

For more than half a century, marijuana sat in Schedule 1, alongside heroin and LSD. Federal law described Schedule 1 drugs as having a high potential for abuse and no accepted medical use.

That classification endured even as most states adopted medical marijuana programs and then adult-use markets, creating a long-running clash between state and federal policy.

The Biden administration began to chip away at that framework. In 2022, President Joe Biden directed health agencies to review marijuana’s status. By 2023, federal health officials recommended shifting the drug to Schedule 3, where substances are recognized as having medical uses and a lower abuse potential than Schedule 1 or 2.

The Justice Department started a formal rulemaking process but left the proposal unfinished when the administration changed.

Trump’s return to the White House revived the issue. Throughout 2025, officials floated the idea that the president favored a “common-sense” change that would keep criminal penalties for serious trafficking but acknowledge state medical programs and research needs.

Markets reacted to every hint that Trump marijuana rescheduling might advance through an executive order.

Reports in early December described internal debate over public health, politics and law enforcement, as well as a new communications strategy: tie rescheduling to a promise to help older Americans through possible Medicare support for CBD.

On Dec. 18, the president signed an executive order in the Oval Office, surrounded by physicians, veterans and senior officials.

The text directs the attorney general to identify and complete the steps needed to move marijuana to Schedule 3 as quickly as the law allows.

Trade press coverage notes that the order explicitly references the size of the legal cannabis industry and the burden of Internal Revenue Code Section 280E, signaling that tax relief is a central goal of Trump marijuana rescheduling.

Meanwhile, Medicare policy has been moving on a separate but related path.

In April 2025, the Centers for Medicare and Medicaid Services finalized a 2026 rule that bars Medicare coverage of marijuana and CBD products, even when those products are derived from federally legal hemp.

Only FDA-approved cannabis-related medications, such as specific CBD prescriptions, are clearly eligible for coverage.

In late November 2025, CMS released a proposed rule for the 2027 Medicare Advantage and Part D contract year that uses narrower language.

Instead of excluding all “cannabis products,” the agency now proposes to exclude only those that are illegal under applicable state or federal law.

That seemingly small change creates room for some compliant hemp-derived CBD products to be offered as special supplemental benefits in certain Medicare Advantage plans.

The Trump administration has now linked that evolving Medicare debate directly to its Trump marijuana rescheduling strategy.

What the executive order actually does

The core substance of the order is straightforward. The Justice Department is instructed to pursue reclassification of marijuana from Schedule 1 to Schedule 3.

Schedule 3 drugs are still controlled substances, but federal law recognizes them as having accepted medical use and a lower potential for abuse than Schedule 1 or 2 drugs.

The order emphasizes two themes. First, it stresses that keeping marijuana in Schedule 1 has hindered scientific research, especially clinical trials that require approval to handle and administer Schedule 1 substances.

Second, it acknowledges that patients and physicians in state-legal programs face unnecessary legal uncertainty when federal law treats their medicine as more dangerous than many opioids.

Rescheduling alone does not legalize marijuana nationwide. Cannabis would remain a controlled substance.

Federal criminal statutes that apply to unlicensed cultivation, distribution and interstate trafficking would still be enforceable.

Agencies such as the Department of Transportation and Department of Defense would retain wide latitude to enforce strict drug policies for safety-sensitive jobs and military service.

The Food and Drug Administration would continue to apply the normal drug-approval process to any product that makes disease treatment claims, regardless of schedule.

Trump marijuana rescheduling therefore changes the legal posture of cannabis but does not erase federal prohibition. Patients in prohibition states, or individuals operating outside regulated systems, would still face criminal risk. That distinction will matter for years.

280E relief and the business side of medical access

While patients feel policy change most directly through access, supply depends on whether medical and adult-use businesses can survive. That is where Section 280E of the tax code becomes critical.

Section 280E prevents companies that “traffic” in Schedule 1 or 2 substances from deducting ordinary business expenses.

State-licensed cannabis operators pay federal income tax on gross income, not net income, which creates effective tax rates that can exceed 70 percent.

Many otherwise viable dispensaries and cultivation sites struggle or fail because of this one provision.

Once marijuana moves to Schedule 3, compliant cannabis businesses would no longer fall under 280E. They would pay federal taxes like other companies, deducting rent, payroll, security, insurance and other operating costs.

Analysts expect that Trump marijuana rescheduling could shift the financial picture significantly, improving margins, stabilizing balance sheets and making it easier to attract investment.

The exact impact will depend on three factors. The first is timing. The DEA still has to complete notice-and-comment rulemaking, which can take months and could be slowed by lawsuits. The second is interpretation.

The IRS will decide how quickly 280E relief applies and whether there are any transition rules. The third is Congress. Lawmakers could choose to codify, expand or narrow the effects of Trump marijuana rescheduling through new legislation.

For patients, these tax questions are not academic. Lower tax burdens can make it easier for dispensaries to lower prices, expand patient discount programs, invest in staff training, and support clinical research partnerships.

If Trump marijuana rescheduling delivers real 280E relief, that could indirectly improve access and quality of care, especially in markets with tight margins such as Arizona’s.

Medicare, CBD and realistic expectations for seniors

The executive order also directs federal agencies to pursue expanded CBD access for Medicare beneficiaries. That piece of the story has generated some of the most optimistic and misleading headlines.

Under current rules for 2026, Medicare does not cover marijuana or CBD products, with limited exceptions for FDA-approved drugs.

Many Arizona seniors pay cash for over-the-counter CBD and for THC-containing products obtained through the state’s medical or adult-use system.

The proposed 2027 Medicare Advantage and Part D rule changes the language around what plans may cover. By focusing the exclusion on products that are illegal under applicable law, CMS appears to create space for some hemp-derived CBD products that comply with federal and state rules to be treated as supplemental benefits.

Policy reporting suggests that this opening would be narrow. Plans would still need to comply with FDA rules, avoid products marketed with unproven medical claims, and steer clear of intoxicating hemp derivatives that regulators increasingly view as a public safety concern.

To add another layer, the administration is exploring a CBD pilot program through the CMS Innovation Center.

That pilot could begin as early as 2026 and would test limited reimbursement for some uses of CBD in defined patient populations.

Officials have floated ideas that range from chronic pain and neuropathy to sleep disorders, but they have not published final parameters.

Patients should hear three key messages through the noise. Medicare does not yet cover general CBD use, and Trump marijuana rescheduling does not instantly change that.

Any future coverage is likely to be narrow, tied either to FDA-approved products or to very specific, tightly monitored benefits. Safety questions, including known liver toxicity and drug-interaction risks at higher CBD doses, will remain at the center of CMS decision-making.

This is an area where practices like The Marijuana Doctor can play a vital role.

Seniors often manage multiple medications, and CBD can interact with blood thinners, seizure drugs and other common prescriptions. Arizona patients will need individual counseling even if Medicare someday helps pay for part of a CBD regimen.

Supporters, critics and unresolved risks

Supporters of Trump marijuana rescheduling inside the administration describe the order as a pragmatic compromise.

They argue that it keeps strong penalties for fentanyl and other high-risk substances while finally recognizing the reality that most Americans live in states with some form of legal cannabis. The political calculus is clear.

Medical marijuana remains popular with voters, especially with seniors and veterans; linking rescheduling to Medicare CBD exploration positions the White House as compassionate and modern without fully embracing national legalization.

Reform advocates are divided. Many celebrate the symbolism and the likely tax relief from 280E, but they highlight what the order does not do. Rescheduling does not automatically expunge criminal records or eliminate federal marijuana arrests.

It does not address immigration consequences or housing and employment discrimination tied to cannabis.

Some policy thinkers warn that Trump marijuana rescheduling could entrench a two-tier system in which well-capitalized companies that can navigate complex federal rules thrive, while small operators and communities harmed by past enforcement continue to face barriers.

Public health conservatives raise different alarms. They argue that moving marijuana to Schedule 3 risks normalizing use at a time when evidence about high-potency products, youth exposure and mental health outcomes is still developing.

They also note that CBD is not risk-free, especially at high doses or in concentrated forms, and that Medicare coverage could drive wider use without adequate long-term safety data.

For patients, the wisest approach is cautious optimism. Trump marijuana rescheduling is an important shift that can ease research, potentially improve affordability and reduce some legal uncertainty.

It does not remove the need for careful clinical guidance, product quality controls or honest conversations about risk.

What this means today for Arizona patients

Arizona already operates a mature adult-use and medical marijuana system, with licensed dispensaries, testing requirements and substantial state tax revenue.

The Trump marijuana rescheduling order does not change the legality of cannabis under Arizona law. State law still governs who qualifies for a medical card, how dispensaries operate and how products are labeled and tested.

The most immediate effects will likely be indirect and delayed. As 280E relief takes hold, Arizona operators may have more flexibility to reinvest in patient services, adjust pricing or expand locations.

Patients could see changes in discount structures, loyalty programs and availability of specialized products such as tinctures, capsules and topicals that often serve medical needs.

Arizona’s large retiree population also makes the state a likely focal point for whatever Medicare CBD coverage emerges from CMS rulemaking and pilot programs.

Many Arizona patients already come to The Marijuana Doctor seeking guidance on combining hemp-derived CBD with THC-dominant products or with conventional prescriptions.

If some CBD products eventually qualify for Medicare Advantage supplemental benefits, the financial calculus for those patients will shift.

That change will not replace the need for a medical marijuana card, particularly for conditions that respond better to THC-containing products, but it could help seniors stretch fixed incomes a bit further.

Clinics such as The Marijuana Doctor will remain on the front lines of patient education. Federal documents are dense, filled with technical definitions and cautious legal phrases. Arizona patients need clear explanations of what Trump marijuana rescheduling does for them today, what might change over the next few years, and how to navigate the overlap between state law and evolving federal rules.

The bottom line is simple, even if the policy is not. Marijuana’s federal status is finally shifting toward reality, and Medicare is tiptoeing toward a more nuanced approach to CBD. Patients still need evidence-based guidance, high-quality products and legal protections.

As the DEA, CMS and Congress work through the next steps, The Marijuana Doctor will continue to focus on what matters most: helping Arizona patients use cannabis medicine safely, effectively and in full awareness of their rights and responsibilities.

***

Marijuana Doctor is your premier destination for seamless medical marijuana licensing. Our compassionate team guides you with expertise, ensuring a smooth process. Discover the therapeutic benefits in a supportive environment that prioritizes your well-being.

Join a community championing alternative healing methods for a healthier life. Choose Marijuana Doctor for personalized, patient-centered care, and step into a revitalized future.

Follow us on Instagram!